Zhejiang Sealant Pharma

Zhejiang Sealant Pharma is a clinical-stage pharmaceutical company headquartered in Hangzhou, China, focused on the development and commercialization of high-end generic and innovative small molecule therapeutics. The company targets therapeutic areas with high clinical demand, particularly cardiovascular diseases, metabolic disorders, and central nervous system conditions. Its lead innovative program, SLN-011, is a URAT1 inhibitor currently in Phase 2 clinical trials for the treatment of hyperuricemia and gout. Sealant Pharma maintains advanced R&D and manufacturing facilities that comply with international GMP standards, enabling the production of complex APIs and finished dosage forms. By combining internal innovation with a robust portfolio of complex generics, the company strives to provide high-quality and cost-effective medical solutions to patients globally.